Patent: 6,235,883
✉ Email this page to a colleague
Summary for Patent: 6,235,883
Title: | Human monoclonal antibodies to epidermal growth factor receptor |
Abstract: | In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. |
Inventor(s): | Jakobovits; Aya (Menlo Park, CA), Yang; Xiao-Dong (Palo Alto, CA), Gallo; Michael (San Jose, CA), Jia; Xiao-Chi (San Mateo, CA) |
Assignee: | Abgenix, Inc. (Fremont, CA) |
Application Number: | 08/851,362 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,235,883 |
Patent Claims: | see list of patent claims |
Details for Patent 6,235,883
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,235,883
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9850433 | ⤷ Try a Trial |
United States of America | 8227580 | ⤷ Try a Trial |
United States of America | 7807798 | ⤷ Try a Trial |
United States of America | 2010305307 | ⤷ Try a Trial |
United States of America | 2006183887 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |